R1	Has_qualifier Arg1:T4 Arg2:T5	
R2	Has_index Arg1:T6 Arg2:T7	
R3	Has_temporal Arg1:T4 Arg2:T6	
*	OR T8 T9
R4	Has_temporal Arg1:T8 Arg2:T10	
*	OR T14 T15
R5	Has_qualifier Arg1:T13 Arg2:T14	
*	OR T13 T16
R6	AND Arg1:T13 Arg2:T18	
R7	AND Arg1:T13 Arg2:T17	
R8	Has_temporal Arg1:T21 Arg2:T22	
*	OR T24 T23
R9	AND Arg1:T25 Arg2:T26	
R10	Has_qualifier Arg1:T29 Arg2:T30	
R11	Has_index Arg1:T31 Arg2:T32	
R13	Has_temporal Arg1:T25 Arg2:T31	
R14	Has_temporal Arg1:T35 Arg2:T34	
R15	AND Arg1:T35 Arg2:T36	
R16	Has_temporal Arg1:T35 Arg2:T37	
R17	Has_index Arg1:T42 Arg2:T43	
*	OR T40 T41
R18	Has_temporal Arg1:T40 Arg2:T42	
*	OR T39 T40
R19	Has_index Arg1:T52 Arg2:T53	
*	OR T54 T55
R20	Has_qualifier Arg1:T45 Arg2:T54	
R21	Subsumes Arg1:T45 Arg2:T46	
R22	Has_temporal Arg1:T45 Arg2:T52	
*	OR T58 T59
R23	Has_qualifier Arg1:T57 Arg2:T58	
R24	Has_index Arg1:T60 Arg2:T61	
R25	Has_temporal Arg1:T57 Arg2:T60	
R26	Has_index Arg1:T63 Arg2:T64	
R27	Has_temporal Arg1:T62 Arg2:T63	
R28	Has_qualifier Arg1:T68 Arg2:T69	
R29	Has_qualifier Arg1:T72 Arg2:T73	
*	OR T75 T76 T77
R30	Has_qualifier Arg1:T78 Arg2:T79	
R31	Has_qualifier Arg1:T75 Arg2:T80	
R32	Has_qualifier Arg1:T77 Arg2:T81	
R34	Has_index Arg1:T70 Arg2:T71	
R35	Has_temporal Arg1:T68 Arg2:T70	
*	OR T85 T86
R36	Has_context Arg1:T85 Arg2:T84	
R37	Has_temporal Arg1:T85 Arg2:T83	
R38	AND Arg1:T93 Arg2:T89	
*	OR T89 T90
R39	Has_temporal Arg1:T90 Arg2:T91	
R40	Has_temporal Arg1:T93 Arg2:T92	
R41	Has_qualifier Arg1:T95 Arg2:T96	
R42	Has_temporal Arg1:T95 Arg2:T94	
*	OR T100 T101 T102
R43	AND Arg1:T99 Arg2:T100	
*	OR T99 T106
R44	Has_temporal Arg1:T107 Arg2:T108	
R45	Has_qualifier Arg1:T109 Arg2:T111	
R46	Has_qualifier Arg1:T109 Arg2:T110	
R47	Has_index Arg1:T114 Arg2:T116	
R48	Has_temporal Arg1:T113 Arg2:T114	
R49	AND Arg1:T112 Arg2:T113	
R50	Has_index Arg1:T118 Arg2:T119	
R51	Has_temporal Arg1:T117 Arg2:T118	
R33	Has_negation Arg1:T72 Arg2:T120	
R52	AND Arg1:T68 Arg2:T72	
*	OR T97 T98 T121 T122
R53	Has_index Arg1:T123 Arg2:T124	
R55	Has_index Arg1:T125 Arg2:T126	
R56	Has_index Arg1:T127 Arg2:T128	
R54	Has_temporal Arg1:T122 Arg2:T123	
R12	Has_negation Arg1:T29 Arg2:T130	
R57	AND Arg1:T25 Arg2:T29	
R58	Has_temporal Arg1:T27 Arg2:T31	
R59	Has_temporal Arg1:T28 Arg2:T31	
R60	Subsumes Arg1:T45 Arg2:T47	
R61	Subsumes Arg1:T45 Arg2:T48	
R62	Subsumes Arg1:T45 Arg2:T49	
R63	Subsumes Arg1:T45 Arg2:T50	
R64	Subsumes Arg1:T45 Arg2:T51	
R65	Has_negation Arg1:T75 Arg2:T120	
R66	Has_negation Arg1:T78 Arg2:T120	
R67	AND Arg1:T68 Arg2:T75	
R68	AND Arg1:T68 Arg2:T78	
R69	Has_temporal Arg1:T122 Arg2:T125	
R70	Has_temporal Arg1:T122 Arg2:T127	
T1	Non-query-able 0 175	Is currently participating or has participated in a study with an investigational agent or using an investigational device within 4 weeks of the first dose of study medication
T2	Drug 190 199	sorafenib
T3	Drug 203 214	oxaliplatin
T4	Procedure 221 233	chemotherapy
T5	Qualifier 190 220	sorafenib or oxaliplatin-based
T6	Temporal 234 248	within 14 days
T7	Reference_point 252 282	first dose of study medication
T8	Condition 292 302;314 331	esophageal variceal bleeding
T9	Condition 306 331	gastric variceal bleeding
T10	Temporal 332 356	within the last 6 months
T12	Condition 382 389	ascites
T13	Condition 419 439	portal vein invasion
T14	Qualifier 447 471	main portal branch (Vp4)
T15	Qualifier 473 491	inferior vena cava
T16	Condition 496 515	cardiac involvement
T17	Condition 519 522	HCC
T18	Procedure 532 539	imaging
T21	Condition 570 592	hepatic encephalopathy
T22	Temporal 593 613	in the last 6 months
T23	Procedure 640 662	hematologic transplant
T24	Procedure 625 636;652 662	solid organ transplant
T25	Procedure 678 694	systemic therapy
T26	Condition 699 702	HCC
T27	Drug 750 759	sorafenib
T28	Drug 763 774	oxaliplatin
T29	Procedure 781 793	chemotherapy
T30	Qualifier 750 780	sorafenib or oxaliplatin-based
T31	Temporal 795 800	prior
T32	Reference_point 804 829	start of study medication
T34	Temporal 838 844	active
T35	Condition 845 863	autoimmune disease
T36	Procedure 882 900	systemic treatment
T37	Temporal 901 920	in the past 2 years
T38	Not_a_criteria 922 989	Replacement therapy is not considered a form of systemic treatment.
T39	Condition 1010 1026	immunodeficiency
T40	Procedure 1043 1067	systemic steroid therapy
T41	Procedure 1089 1114	immunosuppressive therapy
T42	Temporal 1115 1134	within 7 days prior
T43	Reference_point 1138 1172	the first dose of study medication
T45	Procedure 1187 1207	locoregional therapy
T46	Procedure 1218 1256	transcatheter chemoembolization [TACE]
T47	Procedure 1258 1290	transcatheter embolization [TAE]
T48	Procedure 1292 1323	hepatic arterial infusion [HAI]
T49	Procedure 1325 1334	radiation
T50	Procedure 1336 1353	radioembolization
T51	Procedure 1358 1366	ablation
T52	Temporal 1382 1402	within 4 weeks prior
T53	Reference_point 1410 1440	first dose of study medication
T54	Qualifier 1211 1216	liver
T55	Qualifier 1371 1381	other site
T57	Procedure 1450 1463	major surgery
T58	Qualifier 1467 1472	liver
T59	Qualifier 1476 1486	other site
T60	Temporal 1487 1507	within 4 weeks prior
T61	Reference_point 1515 1545	first dose of study medication
T62	Procedure 1557 1570	minor surgery
T63	Temporal 1571 1584	≤7 days prior
T64	Reference_point 1592 1622	first dose of study medication
T65	Undefined_semantics 1624 1763	Has not recovered adequately (i.e., Grade ≤1 or baseline) from the toxicity and/or complications from any intervention prior to study start
T66	Context_Error 1624 1763	Has not recovered adequately (i.e., Grade ≤1 or baseline) from the toxicity and/or complications from any intervention prior to study start
T67	Subjective_judgement 1632 1652	recovered adequately
T68	Condition 1792 1802	malignancy
T69	Qualifier 1781 1791	additional
T70	Temporal 1803 1857	within 3 years prior to first dose of study medication
T71	Reference_point 1827 1857	first dose of study medication
T72	Procedure 1891 1898	treated
T73	Qualifier 1880 1890	curatively
T74	Undefined_semantics 1880 1898	curatively treated
T75	Condition 1899 1931	basal cell carcinoma of the skin
T76	Condition 1933 1968	squamous cell carcinoma of the skin
T77	Condition 1996 2011	in situ cancers
T78	Procedure 1987 1995	resected
T79	Qualifier 1976 1986	curatively
T80	Qualifier 1880 1898	curatively treated
T81	Qualifier 1976 1995	curatively resected
T83	Temporal 2025 2032	history
T84	Observation 2044 2052	evidence
T85	Condition 2057 2096	central nervous system (CNS) metastases
T86	Condition 2104 2128	carcinomatous meningitis
T89	Drug 2190 2198	steroids
T90	Drug 2210 2221	pneumonitis
T91	Temporal 2202 2209	current
T92	Temporal 2136 2143	history
T93	Condition 2148 2175	non-infectious) pneumonitis
T88	Procedure 2257 2273	systemic therapy
T94	Temporal 2230 2236	active
T95	Condition 2237 2246	infection
T96	Qualifier 2247 2273	requiring systemic therapy
T99	Procedure 2502 2515	immunotherapy
T100	Drug 2524 2568	anti-Programmed Cell Death Receptor 1 (PD-1)
T101	Drug 2570 2622	Programmed Cell Death Receptor Ligand 1 (anti-PD-L1)
T102	Drug 2627 2680	anti- Programmed Cell Death Receptor Ligand 2 (PD-L2)
T103	Non-query-able 2699 2750	participated in clinical studies with pembrolizumab
T104	Drug 2737 2750	pembrolizumab
T106	Observation 2699 2750	participated in clinical studies with pembrolizumab
T107	Condition 2775 2809	human immunodeficiency virus (HIV)
T108	Temporal 2764 2771	history
T109	Condition 2832 2843	Hepatitis B
T110	Qualifier 2815 2824	untreated
T111	Qualifier 2825 2831	active
T112	Condition 2849 2860	hepatitis C
T113	Procedure 2892 2907	therapy for HCV
T114	Temporal 2908 2922	<4 weeks prior
T115	Drug 2936 2949	pembrolizumab
T116	Reference_point 2926 2949	receiving pembrolizumab
T117	Condition 2966 2978	live vaccine
T118	Temporal 2986 2999	30 days prior
T119	Reference_point 3007 3034	first dose of study therapy
T120	Negation 1858 1879	with the exception of
T97	Condition 2278 2286	pregnant
T98	Observation 2290 2304	breast feeding
T121	Observation 2308 2329	expecting to conceive
T122	Observation 2308 2320;2333 2339	expecting to father
T123	Temporal 2340 2388	starting from the first dose of study medication
T124	Reference_point 2354 2388	the first dose of study medication
T125	Temporal 2390 2417	throughout the study period
T126	Reference_point 2401 2417	the study period
T127	Temporal 2423 2481	for up to 120 days after the last dose of study medication
T128	Reference_point 2448 2481	the last dose of study medication
T130	Negation 739 749	other than
